Copycats welcome, but Janssen 'wants to be innovator,' says RA lead

2019_biotech_test_vial_discovery_big

Dan Baker says he always harps on about joints; in particular, the fact that they don’t tend to heal very well.

It’s a key driver of his, and his company’s approach to combating rheumatoid arthritis, a debilitating disease that affects up to 20 million people worldwide.

Dr Baker joined Remicade (infliximab) developer Centocor at the time the blockbuster anti-TNF biologic was being developed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology